Abstract:Objective:To analyze the clinical characteristics, treatment and prognosis of patients with thrombotic thrombocytopenic purpura (TTP) .Methods:83 patients with TTP from May 1998 to May 2019 were analyzed retrospectively.Results:Among the 83 patients, there were 27 males and 56 females, with a median age of 39 (10-68) years. 41 cases (49.4%) showed pentalogy syndrome and 79 cases (95.2%) showed triad syndrome. 78.0% (46/59) of the patients had a PLASMIC score of 6 or higher. TTP gene mutations was detected in 5 of 10 patients. The activity of von Willebrand factor-cleaving protease (ADAMTS13) , which was detected in 10 patients before plasma exchange (PEX) , was less than 10% in 9 patients. 83 patients were treated with PEX/plasma infusion and glucocorticoid, 35 of which were treated combined with rituximab and/or immunosuppressant. The median follow-up was 34 (1-167) months, the effective rate was 81.9%, the remission rate was 63.9%, the relapse rate was (35.7 ±7.1) %, and the 3-year overall survival (OS) rate was (78.6 ±4.6) %. The effective rate (72.9% vs 94.3%, P=0.019) and OS rate[ (63.8±7.5) % vs (94.3±3.9) %, χ2=8.450, P=0.004] in the group treated with PEX/PI and glucocorticoid alone were lower than those in the group treated combined with rituximab and/or immunosuppressant. COX multivariate analysis showed that age ( HR=1.111, 95% CI 1.044-1.184, P=0.001) and alanine transaminase (ALT) /aspartate aminotransferase (AST) ( HR=1.353, 95% CI 1.072-1.708, P=0.011) were independent risk factors for OS. Conclusion:Most patients with TTP have triad syndrome, accompanied by a decrease in ADAMTS13 activity. Plasma infusion and glucocorticoid combined with rituximab, immunosuppressive therapy could improve overall survival. The prognosis of patients with older age and high ALT/AST ratio is poor.

Quick Development and Sudden Death: Evans Syndrome Followed by Thrombotic Thrombocytopenic Purpura

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

Thrombotic Thrombocytopenia Purpura (TTP) Following Emergent Aortic Valve Replacement after a Complicated TAVR Procedure: a Case Report and Review of the Literature

Analysis of the Emergency Treatment of Patients With Thrombotic Thrombocytopenic Purpura

Clinical Characteristics of 83 Patients with Thrombotic Thrombocytopenic Purpura

[Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].

Congenital thrombotic thrombocytopenic purpura: Upshaw-Schulman syndrome: a cause of neonatal death and review of literature

A Rare Intersection: Managing Thrombotic Thrombocytopenic Purpura in the Context of Dengue Fever

Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency

Thrombotic thrombocytopenic purpura presenting with variable neurological symptoms：A case report and literature review

[Advances in the treatment of thrombotic thrombocytopenic purpura]

Atypical Presentation of Thrombotic Thrombocytopenic Purpura (TTP) as an Initial Manifestation of Systemic Lupus Erythematosus (SLE) in a Young Male

Neurological manifestations as initial presentations of thrombotic thrombocytopenic purpura:clinical analysis of 26 cases.

Systemic infections mimicking thrombotic thrombocytopenic purpura

S2666 Pancreatic Predicament: Unraveling Thrombotic Thrombocytopenic Purpura Secondary to Acute Pancreatitis - A Case Report

Infection as Trigger for Congenital Thrombotic Thrombocytopenic Purpura in an Adult Patient

COVID-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Treatment-Focused Review

Systemic Sclerosis With Thrombotic Thrombocytopenia Purpura And Malignant Hypertension

Treatment Of Thrombotic Thrombocytopenic Purpura With Heparin Vincristine And Dexamethasone.

The clinical studies of 51 patients with thrombotic thrombocytopenic purpura]